Literature DB >> 10881932

Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1.

H Takamori1, Z G Oades, O C Hoch, M Burger, I U Schraufstatter.   

Abstract

A human pancreatic cancer cell line, Capan-1, secretes the chemokines interleukin-8 (IL-8) and growth-related oncogene alpha (GROalpha). Capan-1 cells also express the chemokine receptor 2 (CXCR2), which is a Gialpha-protein coupled receptor. Growth of Capan-1 cells was inhibited when anti-IL-8 or anti-GROalpha monoclonal antibody was added into the culture medium. Pertussis toxin, which blocks Gialpha also demonstrated a growth-inhibitory effect on Capan-1 cells. These results indicated that IL-8 and GROalpha act on Capan-1 cells as growth factors in an autocrine manner through CXCR2.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10881932     DOI： 10.1097/00006676-200007000-00051

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


  43 in total

1.  EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.

Authors:  R Bonavia; M M Inda; S Vandenberg; S-Y Cheng; M Nagane; P Hadwiger; P Tan; D W Y Sah; W K Cavenee; F B Furnari
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

2.  Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1.

Authors:  K I Amiri; H C Ha; M E Smulson; A Richmond
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 3.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 4.  Chemokines as mediators of tumor angiogenesis and neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Exp Cell Res       Date:  2010-10-30       Impact factor: 3.905

Review 5.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin.

Authors:  Tsutomu Kobayashi; Tatsuo Shimura; Toshiki Yajima; Norio Kubo; Kenichiro Araki; Soichi Tsutsumi; Hideki Suzuki; Hiroyuki Kuwano; Avraham Raz
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

Review 7.  CXC chemokines in cancer angiogenesis and metastases.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

8.  CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth.

Authors:  Shuo Wang; Yanning Wu; Yuning Hou; Xiaoqing Guan; Marcello P Castelvetere; Jacob J Oblak; Sanjeev Banerjee; Theresa M Filtz; Fazlul H Sarkar; Xuequn Chen; Bhanu P Jena; Chunying Li
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

9.  BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.

Authors:  Ashkan Shahbandi; Sonia G Rao; Ashlyn Y Anderson; Wesley D Frey; Joy O Olayiwola; Nathan A Ungerleider; James G Jackson
Journal:  Cell Death Differ       Date:  2020-05-26       Impact factor: 15.828

Review 10.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.